Michelle represents private and public companies at all stages of growth in a range of corporate and securities matters, including corporate governance, private financings, public offerings, Securities and Exchange Commission reporting and compliance, and mergers & acquisitions.
Cidara Therapeutics Announces Concurrent Reacquisition of IP Rights to CD388, $240 Million PIPE Financing
May 1, 2024
Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388.
MannKind Announces up to $200 Million Royalty Purchase Agreement With Sagard Healthcare
January 2, 2024
Cooley advised MannKind, a company focusing on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases, on the sale of a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare for up to $200 million.
RayzeBio Signs Approximately $4.1 Billion Acquisition Agreement With Bristol Myers Squibb
December 26, 2023
Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.
Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.
Red Tree Venture Capital – $108 Million Oversubscribed Series B Financing
March 6, 2023
Cooley advised Red Tree Venture Capital on a $108 million oversubscribed Series B financing – co-led by RA Capital Management – in Bicara Therapeutics, a clinical-stage biotechnology company developing biologics for anti-tumor response.
